AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Company profile
Ticker
AIKI
Exchange
Website
CEO
Anthony Hayes
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • SomaLogic ...
Former names
BIOSPHERICS INC, SPHERIX INC
SEC CIK
Corporate docs
Subsidiaries
AIkido Labs LLC ...
IRS number
520849320
AIKI stock data
News
AIkido Pharma Confirms Receipt Of Unsolicited Offer For $8/Share In Cash
10 Aug 22
AIkido Pharma Announces Shareholder Shalom Auerbach Has Sent Letter Proposing To Acquire Co. For $8/Share
9 Aug 22
Significant Investor In Aikido Pharma Issues Open Letter To Board Of Directors
7 Jun 22
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
7 Jun 22
12 Health Care Stocks Moving In Friday's After-Market Session
3 Jun 22
Press releases
AIkido Pharma Confirms Receipt of Unsolicited Offer
10 Aug 22
AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial Services Subsidiary
21 Jul 22
AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
28 Jun 22
AIkido Inc. Announces the Formation of a New Financial Services Subsidiary
24 Jun 22
Significant Investor in AIkido Pharma Urges Board to Commit to Sell Assets and Return Capital to Stockholders
21 Jun 22
Investment data
Securities sold
Number of investors
Calendar
12 Aug 22
18 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 38.79M | 38.79M | 38.79M | 38.79M | 38.79M | 38.79M |
Cash burn (monthly) | 10.62M | (no burn) | 766K | 872.08K | 678.67K | 818.08K |
Cash used (since last report) | 17.51M | n/a | 1.26M | 1.44M | 1.12M | 1.35M |
Cash remaining | 21.28M | n/a | 37.53M | 37.35M | 37.67M | 37.44M |
Runway (months of cash) | 2.0 | n/a | 49.0 | 42.8 | 55.5 | 45.8 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 May 22 | Hayes Anthony | NQSO Common Stock | Grant | Acquire A | No | No | 0.35 | 1,200,000 | 420K | 1,200,000 |
2 May 22 | Kyle Michael Wool | NQSO Common Stock | Grant | Acquire A | No | No | 0.35 | 1,200,000 | 420K | 1,200,000 |
30 Jul 21 | Gregory James Blattner | Common Stock | Grant | Acquire A | No | No | 0.88 | 25,000 | 22K | 61,766 |
30 Jul 21 | Tim S Ledwick | Common Stock | Grant | Acquire A | No | No | 0.88 | 25,000 | 22K | 69,756 |
30 Jul 21 | Robert J VanderZanden | Common Stock | Grant | Acquire A | No | No | 0.88 | 25,000 | 22K | 68,570 |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Management Discussion
- The Company experienced very little or no revenue in the last two years and we don’t expect any revenue until a biotechnology product is fully developed which may not occur for many years.
- For the year ended December 31, 2021 and 2020, we incurred a loss from operations of $9.4 million and $6.5 million, respectively. The increase in loss was primarily attributed to $3.6 million increase in general and administrative expenses, partially offset by $0.5 million decrease in research and development expense incurred in connection with the license acquired, and $0.3 million decrease in other research and development expense. In 2021, we engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build our investment processes. Kyle Wool, Board Member, is the president of Revere. We incurred fees of approximately $1.2 million during the year December 31, 2021. These fees were included in general and administrative expense.
- For the year ended December 31, 2021 and 2020, other income was approximately $2.3 million and $ Other expenses was approximately $5.8 million, respectively. The increase in other income was primarily attributed to a $10.4 million increase in fair value of investment, and partially offset by $2.7 million decrease in gains on marketable securities.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adding, Aldavero, Amazon, American, Anduril, Anthony, authorized, automation, buyback, Certificate, China, Connexa, criteria, defense, Discord, divested, Europe, FINRA, high, India, Jeffrey, long, national, owed, phase, popular, program, renewable, replaced, Repurchase, repurchased, retired, retrospectively, Revere, reverse, salary, satisfied, Secretary, Serial, split, thousand, Thrasio, top, treasury, USPTO
Removed:
antigen, Bander, conducting, Cornell, evaluated, human, Medicine, membrane, Neil, peptide, present, Professor, prostate, PRRT, PSMA, radionuclide, receptor, Urologic, utilizing, valuate, Weill
Financial reports
Current reports
8-K
Changes in Registrant's Certifying Accountant
6 Jul 22
8-K
Other Events
28 Jun 22
8-K
AIkido Pharma Inc. Appoints New Director, Soo Yu
10 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
25 May 22
8-K
Other Events
30 Mar 22
8-K
AIkido Pharma Inc. Announces $22 Million Registered Direct Offering
2 Mar 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Feb 22
8-K
AIkido Pharma Announces Share Repurchase Program
24 Jan 22
8-K
Submission of Matters to a Vote of Security Holders
9 Dec 21
8-K
Submission of Matters to a Vote of Security Holders
9 Nov 21
Registration and prospectus
424B5
Prospectus supplement for primary offering
1 Mar 22
424B5
Prospectus supplement for primary offering
1 Mar 22
RW
Registration withdrawal request
21 Apr 21
424B5
Prospectus supplement for primary offering
18 Feb 21
424B5
Prospectus supplement for primary offering
15 Feb 21
S-1/A
IPO registration (amended)
26 Aug 20
S-1
IPO registration
17 Aug 20
S-3/A
Shelf registration (amended)
8 Jun 20
S-3
Shelf registration
11 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
9 Nov 21
DEFA14A
Additional proxy soliciting materials
2 Nov 21
DEFA14A
Additional proxy soliciting materials
1 Oct 21
DEFA14A
Additional proxy soliciting materials
4 Dec 20
DEFA14A
Additional proxy soliciting materials
25 Nov 20
DEF 14A
Definitive proxy
5 Oct 20
PRE 14A
Preliminary proxy
23 Sep 20
Other
EFFECT
Notice of effectiveness
19 Jun 20
CORRESP
Correspondence with SEC
15 Jun 20
CORRESP
Correspondence with SEC
11 Jun 20
UPLOAD
Letter from SEC
10 Jun 20
CORRESP
Correspondence with SEC
7 Jun 20
UPLOAD
Letter from SEC
21 May 20
EFFECT
Notice of effectiveness
4 Mar 20
CORRESP
Correspondence with SEC
1 Mar 20
CORRESP
Correspondence with SEC
1 Mar 20
CORRESP
Correspondence with SEC
27 Feb 20
Ownership
SC 13G
AIkido Pharma / INTRACOASTAL CAPITAL ownership change
14 Jun 22
4
AIkido Pharma / Kyle Michael Wool ownership change
4 May 22
4
AIkido Pharma / Anthony Hayes ownership change
4 May 22
SC 13G/A
AIkido Pharma / CVI Investments ownership change
14 Feb 22
4
AIkido Pharma / Robert J VanderZanden ownership change
30 Jul 21
4
AIkido Pharma / Kyle Michael Wool ownership change
30 Jul 21
4
AIkido Pharma / Paul LeMire ownership change
30 Jul 21
4
AIkido Pharma / TIM S LEDWICK ownership change
30 Jul 21
4
AIkido Pharma / Robert Frederick Dudley ownership change
30 Jul 21
4
AIkido Pharma / Gregory James Blattner ownership change
30 Jul 21
Reddit threads
Daily Discussion Thread - August 17th, 2022
17 Aug 22
Daily Discussion Thread - August 16th, 2022
16 Aug 22
Daily Discussion Thread - August 10th, 2022
10 Aug 22
Daily Discussion Thread - August 9th, 2022
9 Aug 22
Daily Discussion Thread - May 17th, 2022
17 May 22
Daily Discussion Thread - May 16th, 2022
16 May 22
$AIKI's journey from $200,000 to .30 ...
12 May 22
Daily Discussion Thread - May 10th, 2022
10 May 22
Daily Discussion Thread - May 9th, 2022
9 May 22
Daily Plays April 05, 2022
5 Apr 22